查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美放射性藥物治療市場預測至 2028 年 - 區域分析 - 按產品類型、放射性同位素、來源、應用、適應症和最終用戶
市場調查報告書
商品編碼
1463668

北美放射性藥物治療市場預測至 2028 年 - 區域分析 - 按產品類型、放射性同位素、來源、應用、適應症和最終用戶

North America Radiopharmaceutical Theranostics Market Forecast to 2028 - Regional Analysis - by Product Type, Radioisotope, Source, Application, Indication, and End User
出版日期: | 出版商: The Insight Partners | 英文 185 Pages | 訂單完成後即時交付

價格

2022年北美放射性藥物治療診斷市值為7.9588億美元，預計2028年將達到15.2995億美元；預計2022年至2028年CAGR為11.5%。

在心血管疾病治療的應用不斷增加

心血管疾病（CVD）是21世紀最常見的慢性疾病之一，死亡率很高。由於久坐的生活方式，心血管疾病是已開發國家死亡和發病的主要原因。此外，肥胖和糖尿病以及相關疾病與心血管疾病有關，並且正在成為共病。此外，冠狀動脈阻塞等併發症是成人死亡的首要原因之一，導致動脈壁內膜（主要是頸動脈）形成血栓斑塊。心血管疾病的治療應用包括奈米藥物在心絞痛、心肌炎、心肌梗塞、心包膜疾病、血栓形成、動脈粥狀硬化、高血脂、高血壓、肺動脈高壓和中風的應用。治療診斷奈米藥物可以延長體循環，逃避宿主防禦系統，並將治療診斷劑遞送到目標部位，以在細胞和分子層面上進行成像和治療。

根據美國疾病管制與預防中心 (CDC) 2022 年的報告，心臟病是美國男性和女性死亡的主要原因。 2020 年，心臟病導致美國約697,000 人死亡，即五分之一的死亡。克服複雜性和病理生理學問題與 CVD 相關的併發症。動脈粥狀硬化患者的心血管影像提供了有助於治療心血管疾病的病理生理學證據。此外，治療診斷奈米顆粒可以與一系列成像技術相結合，例如磁振造影、正子斷層掃描（PET）和電腦斷層掃描（CT）。迄今為止，已經在臨床實驗室進行了各種臨床研究。透過將聚合物光聲探針與奈米顆粒 PLCDP@PMH 結合，建構了三合一治療複合物。臨床體內評估表明，PLCDP@PMH 為患者早期動脈粥狀硬化檢測的治療診斷方法提供了有利可圖的優勢。

北美放射性藥物治療市場概述

北美放射性藥物治療診斷市場分為美國、加拿大和墨西哥。預計美國將成為放射性藥物治療市場的最大貢獻者之一。該地區的市場成長歸因於慢性病發病率的增加、政府支持計劃的存在、市場參與者不斷成長的戰略舉措以及創新放射療法的發展。

北美放射性藥物治療市場收入及 2028 年預測（百萬美元）

北美放射性藥物治療診斷市場細分

北美放射性藥物治療診斷市場分為產品類型、放射性同位素、來源、應用、適應症、最終用戶和國家。根據產品類型，北美放射性藥物治療診斷市場分為 α 發射器、BETA 發射器和正子斷層掃描 (PET) 示踪劑。 2022 年，PET 示踪劑領域佔據最大的市場佔有率。

根據放射性同位素，北美放射性藥物治療市場分為锝-99、鎵-68、碘-131、碘-123、氟-18 (18F)、釔 90 (Y-90)、鎧 (Lu) 177、銅（ Cu）67、銅（Cu）64等。镥 (Lu) 177 細分市場在 2022 年佔據最大的市場佔有率。

根據消息來源，北美放射性藥物治療診斷市場分為核反應器和迴旋加速器。到 2022 年，迴旋加速器領域將佔據更大的市場佔有率。

根據應用，北美放射性藥物治療診斷市場分為標靶治療 (Rx) 和伴隨診斷 (CDx)。 2022 年，標靶治療 (Rx) 領域佔據了更大的市場佔有率。

根據適應症，北美放射性藥物治療診斷市場分為腫瘤學、心臟科、神經學等。 2022 年，腫瘤學領域佔據最大的市場。

根據最終用戶，北美放射性藥物治療診斷市場分為醫院、診斷影像中心、學術和研究機構等。 2022 年，腫瘤學領域佔據最大的市場。

按國家/地區分類，北美放射性藥物治療診斷市場分為美國、加拿大和墨西哥。 2022 年，美國在北美放射性藥物治療診斷市場佔有率中佔據主導地位。

拜耳公司；通用電氣醫療保健技術公司；鋦; Lantheus 醫學影像公司； Telix 製藥有限公司；康德樂健康公司；高級加速器應用 SA；歡欣鼓舞的放射製藥公司；治療診斷學；和 NuView Life Sciences 是北美放射性藥物治療市場的領先公司。

目錄

第 1 章：簡介

第 2 章：放射性藥物治療市場 - 要點

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：北美放射性藥物治療診斷市場 - 市場格局

  • 概述
  • PEST分析
    • 北美 PEST 分析
  • 專家意見

第 5 章：北美放射性藥物治療診斷市場 - 主要市場動態

  • 市場促進因素
    • 癌症發生率上升
    • 在心血管疾病治療的應用不斷增加
  • 市場限制
    • 批准放射性藥物治療的監管挑戰
  • 市場機會
    • 用於個人化放射性藥物治療的治療診斷數位孿生
  • 未來的趨勢
    • 核子醫學中的放射性藥物治療診斷學
  • 影響分析

第 6 章：放射性藥物治療市場 - 北美分析

  • 北美放射性藥物治療市場收入預測與分析

第 7 章：北美放射性藥物治療市場 - 2028 年收入與預測 - 按產品類型

  • 概述
  • 2021 年和 2028 年按產品類型分類的放射性藥物治療市場收入佔有率 (%)

第 8 章：北美放射性藥物治療市場分析 - 按放射性同位素

  • 概述
  • 2021 年和 2028 年放射性藥物治療市場收入佔有率（按放射性同位素分類）（%）

第 9 章：北美放射性藥物治療市場分析 - 按來源

  • 概述
  • 2021 年及 2028 年放射性藥物治療市場收入佔有率（按來源分類）（%）

第 10 章：北美放射性藥物治療市場分析 - 按應用

  • 概述
  • 2021 年和 2028 年按應用分類的放射性藥物治療市場收入佔有率 (%)

第 11 章：北美放射性藥物治療市場分析 - 按適應症

  • 概述
  • 2021 年和 2028 年按適應症分類的放射性藥物治療市場收入佔有率 (%)

第 12 章：北美放射性藥物治療市場分析 - 按最終用戶

  • 概述
  • 2021 年和 2028 年按最終用戶分類的放射性藥物治療市場收入佔有率 (%)

第 13 章：北美放射性藥物治療市場 - 收入和 2028 年預測 - 按國家分析

  • 北美洲

第 14 章：放射性藥物治療市場 - 產業格局

  • 概述
  • 放射性藥物治療市場的成長策略
  • 無機成長策略
    • 概述
  • 有機成長策略
    • 概述

第 15 章：公司簡介

  • Bayer AG
  • GE HealthCare Technologies Inc
  • Curium
  • Lantheus Medical Imaging, Inc.
  • Telix Pharmaceuticals Ltd.
  • Cardinal Health Inc
  • Advanced Accelerator Applications S.A.
  • Jubilant Radiopharma
  • Theragnostics
  • NuView Life Sciences

第 16 章：附錄

Product Code: BMIRE00028187

The North America radiopharmaceutical theranostics market was valued at US$ 795.88 million in 2022 and is expected to reach US$ 1,529.95 million by 2028; it is estimated to register a CAGR of 11.5% from 2022 to 2028.

Rising Application in Treatment of Cardiovascular Disorders

Cardiovascular diseases (CVDs) are among the most prevalent chronic diseases of the 21st century, with a high mortality rate. Due to their sedentary lifestyle, CVDs are the leading cause of mortality and morbidity in developed countries. In addition, obesity and diabetes, and related diseases are associated with cardiovascular disease and are becoming comorbid. In addition, a complication such as coronary artery obstruction is one of the number one causes of death in adults, resulting in thrombus plaque in the intima of the arterial wall, mainly in the carotid artery. Therapeutic applications in cardiovascular diseases include nanomedicine in angina pectoris, myocarditis, myocardial infarction, pericardial disease, thrombosis, atherosclerosis, hyperlipidemia, hypertension, pulmonary arterial hypertension, and stroke. Theranostic nanomedicines can prolong systemic circulation, evade host defense systems, and deliver theranostic agents to the target site for imaging and therapy at the cellular and molecular levels.

As per the 2022 report by the Centers for Disease Control and Prevention (CDC), heart disease is a leading cause of death among men and women in the US. Heart disease was a cause of ~697,000 deaths, i.e., 1 in 5 deaths, in the US in 2020. A National Institute of Health report states that theranostic nanoparticles have gained significant attention in the medical field, as the techniques help overcome complexities and pathophysiological complications associated with CVDs. Cardiovascular imaging of atherosclerosis patients provides pathophysiological evidence that can help treat CVDs. Further, theranostic nanoparticles can be combined with a range of imaging techniques, such as magnetic resonance imaging, positron emission tomography (PET), and computed tomography (CT). Various clinical research studies have been conducted in clinical laboratories so far. A three-in-one therapeutic complex has been constructed, by combining a polymeric photoacoustic probe with nanoparticles-PLCDP@PMH. Clinical in-vivo evaluations reveal that the PLCDP@PMH provides lucrative advantages for the theranostics approach to early-stage atherosclerosis detection in patients.

North America Radiopharmaceutical Theranostics Market Overview

The North America radiopharmaceutical theranostics market is segmented into US, Canada, and Mexico. The US is expected to be among the largest contributors to the radiopharmaceutical theranostics market. The market growth in this region is due to the increasing incidences of chronic diseases, presence of supportive government plans, growing strategic initiatives by the market players, and development of innovative radiotherapies.

North America Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)

North America Radiopharmaceutical Theranostics Market Segmentation

The North America radiopharmaceutical theranostics market is segmented into product type, radioisotope, source, application, indication, end user, and country. Based on product type, the North America radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The PET tracers segment held the largest market share in 2022.

Based on radioisotope, the North America radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.

Based on source, the North America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.

Based on application, the North America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and Companion Diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in 2022.

Based on indication, the North America radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.

Based on end user, the North America radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The oncology segment held the largest market share in 2022.

Based on country, the North America radiopharmaceutical theranostics market is segmented into the US, Canada, and Mexico. The US dominated the North America radiopharmaceutical theranostics market share in 2022.

Bayer AG; GE Healthcare Technologies Inc.; Curium; Lantheus Medical Imaging, Inc.; Telix Pharmaceuticals Ltd.; Cardinal Health Inc.; Advanced Accelerator Applications S.A; Jubilant Radiopharma; Theragnostics; and NuView Life Sciences are the leading companies operating in the North America radiopharmaceutical theranostics market.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 North America Radiopharmaceutical Theranostics Market - by Product Type
    • 1.3.2 North America Radiopharmaceutical Theranostics Market - by Radioisotope
    • 1.3.3 North America Radiopharmaceutical Theranostics Market - by Source
    • 1.3.4 North America Radiopharmaceutical Theranostics Market - by Application
    • 1.3.5 North America Radiopharmaceutical Theranostics Market - by Indication
    • 1.3.6 North America Radiopharmaceutical Theranostics Market - by End User
    • 1.3.7 North America Radiopharmaceutical Theranostics Market - by Country

2. Radiopharmaceutical Theranostics Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Radiopharmaceutical Theranostics Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America PEST Analysis
  • 4.3 Expert's Opinion

5. North America Radiopharmaceutical Theranostics Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Incidence of Cancer
    • 5.1.2 Rising Application in Treatment of Cardiovascular Disorders
  • 5.2 Market Restraints
    • 5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics
  • 5.3 Market Opportunities
    • 5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies
  • 5.4 Future Trends
    • 5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine
  • 5.5 Impact Analysis

6. Radiopharmaceutical Theranostics Market - North America Analysis

  • 6.1 North America Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis

7. North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type

  • 7.1 Overview
  • 7.2 Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
    • 7.2.1 Positron Emission Tomography (PET) Tracers
      • 7.2.1.1 Overview
      • 7.2.1.2 Positron Emission Tomography (PET) Tracers: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.2.2 Beta Emitters
      • 7.2.2.1 Overview
      • 7.2.2.2 Beta Emitters: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.2.3 Alpha Emitters
      • 7.2.3.1 Overview
      • 7.2.3.2 Alpha Emitters: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

8. North America Radiopharmaceutical Theranostics Market Analysis - by Radioisotope

  • 8.1 Overview
  • 8.2 Radiopharmaceutical Theranostics Market Revenue Share, by Radioisotope 2021 & 2028 (%)
    • 8.2.1 Technetium-99
      • 8.2.1.1 Overview
      • 8.2.1.2 Technetium-99: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.2 Gallium-68
      • 8.2.2.1 Overview
      • 8.2.2.2 Gallium-68: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.3 Iodine-131
      • 8.2.3.1 Overview
      • 8.2.3.2 Iodine-131: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.4 Iodine-123
      • 8.2.4.1 Overview
      • 8.2.4.2 Iodine-123: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.5 Fluorine-18 (18F)
      • 8.2.5.1 Overview
      • 8.2.5.2 Fluorine-18 (18F): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.6 Yttrium 90 (Y-90)
      • 8.2.6.1 Overview
      • 8.2.6.2 Yttrium 90 (Y-90): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.7 Lutetium (LU) 177
      • 8.2.7.1 Overview
      • 8.2.7.2 Lutetium (LU) 177: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.8 Copper (CU) 67
      • 8.2.8.1 Overview
      • 8.2.8.2 Copper (CU) 67: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.9 Copper (CU) 64
      • 8.2.9.1 Overview
      • 8.2.9.2 Copper (CU) 64: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 8.2.10 Others
      • 8.2.10.1 Overview
      • 8.2.10.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

9. North America Radiopharmaceutical Theranostics Market Analysis - by Source

  • 9.1 Overview
  • 9.2 Radiopharmaceutical Theranostics Market Revenue Share, by Source 2021 & 2028 (%)
    • 9.2.1 Nuclear Reactors
      • 9.2.1.1 Overview
      • 9.2.1.2 Nuclear Reactors: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 9.2.2 Cyclotrons
      • 9.2.2.1 Overview
      • 9.2.2.2 Cyclotrons: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

10. North America Radiopharmaceutical Theranostics Market Analysis - by Application

  • 10.1 Overview
  • 10.2 Radiopharmaceutical Theranostics Market Revenue Share, by Application 2021 & 2028 (%)
    • 10.2.1 Targeted Therapeutic (Rx)
      • 10.2.1.1 Overview
      • 10.2.1.2 Targeted Therapeutics (Rx): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 10.2.2 Companion Diagnostic (CDx)
      • 10.2.2.1 Overview
      • 10.2.2.2 Companion Diagnostics (CDx): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

11. North America Radiopharmaceutical Theranostics Market Analysis - by Indication

  • 11.1 Overview
  • 11.2 Radiopharmaceutical Theranostics Market Revenue Share, by Indication 2021 & 2028 (%)
    • 11.2.1 Oncology
      • 11.2.1.1 Overview
      • 11.2.1.2 Oncology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.2.2 Neurology
      • 11.2.2.1 Overview
      • 11.2.2.2 Neurology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.2.3 Cardiology
      • 11.2.3.1 Overview
      • 11.2.3.2 Cardiology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 11.2.4 Others
      • 11.2.4.1 Overview
      • 11.2.4.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

12. North America Radiopharmaceutical Theranostics Market Analysis - by End User

  • 12.1 Overview
  • 12.2 Radiopharmaceutical Theranostics Market Revenue Share, by End User 2021 & 2028 (%)
    • 12.2.1 Hospitals
      • 12.2.1.1 Overview
      • 12.2.1.2 Hospitals: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 12.2.2 Diagnostic Imaging Centers
      • 12.2.2.1 Overview
      • 12.2.2.2 Diagnostic Imaging Centers: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 12.2.3 Academic & Research Institutes
      • 12.2.3.1 Overview
      • 12.2.3.2 Academic & Research Institutes: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    • 12.2.4 Others
      • 12.2.4.1 Overview
      • 12.2.4.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

13. North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Country Analysis

  • 13.1 North America: Radiopharmaceutical Theranostics Market
    • 13.1.1 Overview
      • 13.1.1.1 United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
        • 13.1.1.1.1 Overview
        • 13.1.1.1.2 United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
        • 13.1.1.1.3 United States Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
        • 13.1.1.1.4 United States Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
        • 13.1.1.1.5 United States Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
        • 13.1.1.1.6 United States Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
        • 13.1.1.1.7 United States Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
        • 13.1.1.1.8 United States Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
      • 13.1.1.2 Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
        • 13.1.1.2.1 Overview
        • 13.1.1.2.2 Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
        • 13.1.1.2.3 Canada Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
        • 13.1.1.2.4 Canada Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
        • 13.1.1.2.5 Canada Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
        • 13.1.1.2.6 Canada Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
        • 13.1.1.2.7 Canada Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
        • 13.1.1.2.8 Canada Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
      • 13.1.1.3 Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
        • 13.1.1.3.1 Overview
        • 13.1.1.3.2 Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
        • 13.1.1.3.3 Mexico Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
        • 13.1.1.3.4 Mexico Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
        • 13.1.1.3.5 Mexico Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
        • 13.1.1.3.6 Mexico Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
        • 13.1.1.3.7 Mexico Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
        • 13.1.1.3.8 Mexico Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)

14. Radiopharmaceutical Theranostics Market - Industry Landscape

  • 14.1 Overview
  • 14.2 Growth Strategies in the Radiopharmaceutical Theranostics Market
  • 14.3 Inorganic Growth Strategies
    • 14.3.1 Overview
  • 14.4 Organic Growth Strategies
    • 14.4.1 Overview

15. Company Profiles

  • 15.1 Bayer AG
    • 15.1.1 Key Facts
    • 15.1.2 Business Description
    • 15.1.3 Products and Services
    • 15.1.4 Financial Overview
    • 15.1.5 SWOT Analysis
    • 15.1.6 Key Developments
  • 15.2 GE HealthCare Technologies Inc
    • 15.2.1 Key Facts
    • 15.2.2 Business Description
    • 15.2.3 Products and Services
    • 15.2.4 Financial Overview
    • 15.2.5 SWOT Analysis
    • 15.2.6 Key Developments
  • 15.3 Curium
    • 15.3.1 Key Facts
    • 15.3.2 Business Description
    • 15.3.3 Products and Services
    • 15.3.4 Financial Overview
    • 15.3.5 SWOT Analysis
    • 15.3.6 Key Developments
  • 15.4 Lantheus Medical Imaging, Inc.
    • 15.4.1 Key Facts
    • 15.4.2 Business Description
    • 15.4.3 Products and Services
    • 15.4.4 Financial Overview
    • 15.4.5 SWOT Analysis
    • 15.4.6 Key Developments
  • 15.5 Telix Pharmaceuticals Ltd.
    • 15.5.1 Key Facts
    • 15.5.2 Business Description
    • 15.5.3 Products and Services
    • 15.5.4 Financial Overview
    • 15.5.5 SWOT Analysis
    • 15.5.6 Key Developments
  • 15.6 Cardinal Health Inc
    • 15.6.1 Key Facts
    • 15.6.2 Business Description
    • 15.6.3 Products and Services
    • 15.6.4 Financial Overview
    • 15.6.5 SWOT Analysis
    • 15.6.6 Key Developments
  • 15.7 Advanced Accelerator Applications S.A.
    • 15.7.1 Key Facts
    • 15.7.2 Business Description
    • 15.7.3 Products and Services
    • 15.7.4 Financial Overview
    • 15.7.5 SWOT Analysis
    • 15.7.6 Key Developments
  • 15.8 Jubilant Radiopharma
    • 15.8.1 Key Facts
    • 15.8.2 Business Description
    • 15.8.3 Products and Services
    • 15.8.4 Financial Overview
    • 15.8.5 SWOT Analysis
    • 15.8.6 Key Developments
  • 15.9 Theragnostics
    • 15.9.1 Key Facts
    • 15.9.2 Business Description
    • 15.9.3 Products and Services
    • 15.9.4 Financial Overview
    • 15.9.5 SWOT Analysis
    • 15.9.6 Key Developments
  • 15.10 NuView Life Sciences
    • 15.10.1 Key Facts
    • 15.10.2 Business Description
    • 15.10.3 Products and Services
    • 15.10.4 Financial Overview
    • 15.10.5 SWOT Analysis
    • 15.10.6 Key Developments

16. Appendix

  • 16.1 About The Insight Partners
  • 16.2 Glossary of Terms

List Of Tables

  • Table 1. United States Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. United States Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. United States Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. United States Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. United States Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. United States Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. Canada Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. Canada Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. Canada Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. Canada Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. Canada Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. Canada Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • Table 13. Mexico Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Mexico Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. Mexico Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Mexico Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Mexico Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Mexico Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • Table 19. Recent Inorganic Growth Strategies in the Radiopharmaceutical Theranostics Market
  • Table 20. Recent Organic Growth Strategies in the Radiopharmaceutical Theranostics Market
  • Table 21. Glossary of Terms

List Of Figures

  • Figure 1. North America Radiopharmaceutical Theranostics Market Segmentation
  • Figure 2. North America Radiopharmaceutical Theranostics Market, by Country
  • Figure 3. North America Radiopharmaceutical Theranostics Market Overview
  • Figure 4. Positron Emission Tomography (PET) Tracers Segment Held Largest Share of Product Type Segment in Radiopharmaceutical Theranostics Market
  • Figure 5. US Expected to Show Remarkable Growth During Forecast Period
  • Figure 6. North America: PEST Analysis
  • Figure 7. North America Experts' Opinion
  • Figure 8. North America Radiopharmaceutical Theranostics Market: Impact Analysis of Drivers and Restraints
  • Figure 9. North America Radiopharmaceutical Theranostics Market - Revenue Forecast and Analysis - 2020-2028
  • Figure 10. North America Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
  • Figure 11. Positron Emission Tomography (PET) Tracers: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. Beta Emitters: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. Alpha Emitters: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. North America Radiopharmaceutical Theranostics Market, by Radioisotope, 2021 & 2028 (%)
  • Figure 15. Technetium-99: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 16. Gallium-68: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. Iodine-131: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 18. Iodine-123: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 19. Fluorine-18 (18F): North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Yttrium 90 (Y-90): North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Lutetium (LU) 177: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. Copper (CU) 67: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 23. Copper (CU) 64: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Others: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. North America Radiopharmaceutical Theranostics Market, by Source, 2021 & 2028 (%)
  • Figure 26. Nuclear Reactors: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 27. Cyclotrons: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 28. North America Radiopharmaceutical Theranostics Market, by Application, 2021 & 2028 (%)
  • Figure 29. Targeted Therapeutics (Rx): North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. Companion Diagnostics (CDx): North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 31. North America Radiopharmaceutical Theranostics Market, by Indication, 2021 & 2028 (%)
  • Figure 32. Oncology: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Neurology: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. Cardiology: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 35. Others: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 36. North America Radiopharmaceutical Theranostics Market, by End User, 2021 & 2028 (%)
  • Figure 37. Hospitals: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 38. Diagnostic Imaging Centers: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 39. Academic & Research Institutes: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 40. Others: North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 41. North America: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 42. North America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  • Figure 43. United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 44. Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 45. Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 46. Growth Strategies in the Radiopharmaceutical Theranostics Market